Aclaris Therapeutics ACRS reported its Q4 earnings results on Tuesday, February 27, 2024 at 07:00 AM.
Here's what investors need to know about the announcement.
Earnings
Aclaris Therapeutics beat estimated earnings by 12.0%, reporting an EPS of $-0.3 versus an estimate of $-0.34.
Revenue was up $9.82 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.07 which was followed by a 1.0% drop in the share price the next day.
Here's a look at Aclaris Therapeutics's past performance:
Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
---|---|---|---|---|
EPS Estimate | -0.48 | -0.45 | -0.44 | -0.45 |
EPS Actual | -0.41 | -0.42 | -0.42 | -0.41 |
Revenue Estimate | 1.57M | 1.90M | 1.75M | 1.99M |
Revenue Actual | 9.28M | 1.87M | 2.53M | 7.75M |
To track all earnings releases for Aclaris Therapeutics visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.